Media headlines about Cantel Medical (NYSE:CMD) have trended positive on Monday, according to Accern. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cantel Medical earned a media sentiment score of 0.28 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.3681497425311 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Shares of Cantel Medical (NYSE:CMD) traded up $0.76 during mid-day trading on Monday, hitting $106.84. 81,436 shares of the company were exchanged, compared to its average volume of 154,810. The company has a quick ratio of 1.48, a current ratio of 2.44 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $4,470.00, a PE ratio of 59.03 and a beta of 1.25. Cantel Medical has a 52-week low of $69.21 and a 52-week high of $108.00.
The firm also recently disclosed a Semi-Annual dividend, which will be paid on Wednesday, January 31st. Investors of record on Wednesday, January 17th will be issued a $0.085 dividend. The ex-dividend date is Tuesday, January 16th. This represents a dividend yield of 0.17%. This is a boost from Cantel Medical’s previous Semi-Annual dividend of $0.07. Cantel Medical’s payout ratio is 7.73%.
In related news, Director George L. Fotiades sold 6,000 shares of Cantel Medical stock in a transaction that occurred on Friday, October 13th. The shares were sold at an average price of $95.23, for a total value of $571,380.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Eric W. Nodiff sold 2,868 shares of Cantel Medical stock in a transaction that occurred on Friday, October 20th. The shares were sold at an average price of $97.55, for a total transaction of $279,773.40. Following the completion of the transaction, the executive vice president now owns 39,102 shares of the company’s stock, valued at approximately $3,814,400.10. The disclosure for this sale can be found here. Insiders own 12.30% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Favorable News Coverage Somewhat Unlikely to Impact Cantel Medical (CMD) Share Price” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://ledgergazette.com/2018/01/09/favorable-news-coverage-somewhat-unlikely-to-impact-cantel-medical-cmd-share-price.html.
About Cantel Medical
Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.
Receive News & Ratings for Cantel Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical and related companies with MarketBeat.com's FREE daily email newsletter.